Arvinas, Inc. presented preclinical data for ARV-393 and glofitamab in a humanized high-grade B-cell lymphoma cell line–derived xenograft model, showing enhanced tumor growth inhibition compared to either agent alone. The combination is set to initiate a Phase 1 clinical trial in 2026 for diffuse large B-cell lymphoma. The data suggest synergistic antitumor activity between BCL6 degradation with ARV-393 and T-cell engagement with glofitamab. ARV-393 is an investigational PROTAC designed to target and degrade BCL6, a key driver of B-cell lymphomas. Arvinas aims to provide a chemotherapy-free treatment strategy for patients in need through its protein degradation therapies.

Read more at GlobeNewswire: Arvinas Presents Preclinical Data Supporting Mechanistic